Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 1, 2009, Pages 103-114

  Seng, K Y ^a   Fun, C Y ^a   Law, Y L ^a   Lim, W M ^b   Fan, W ^a   Lim, C L ^a  

^a DSO NATIONAL LABORATORIES   (Singapore)

^b Performance Maximization Branch   (Singapore)

Author keywords

Caffeine; NONMEM; Pharmacokinetics; Population modelling; Stochastic simulation

Indexed keywords

CAFFEINE;

AREA UNDER THE CURVE; ARTICLE; ASIAN; BODY WEIGHT; CIGARETTE SMOKING; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SINGAPORE; SINGLE DRUG DOSE;

ASIAN CONTINENTAL ANCESTRY GROUP; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PROSPECTIVE STUDIES; SINGAPORE; SMOKING; STOCHASTIC PROCESSES; YOUNG ADULT;

EID: 58149288054     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00976.x     Document Type: Article

References (30)

1. Smit HJ, Rogers PJ (2000) Effects of low doses of caffeine on cognitive performance, mood, and thirst in low and higher caffeine consumers. Pyschopharmacology, 152, 167 173.
2. Brice CF, Smith AP (2002) Effects of caffeine on mood and performance: a study of realistic consumption. Psychopharmacology, 164, 188 192.
3. Van Dongen HP, Price NJ, Mullington JM, Szuba MP, Kapoor SC, Dinges DF (2001) Caffeine eliminates psychomotor vigilance deficits from sleep inertia. Sleep, 24, 813 819.
4. Boutrel B, Koob GF (2004) What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep, 27, 1181 1194.
5. Lieberman HR, Tharion WJ, Shukitt-Hale B, Speckman KL, Tulley R (2002) Effects of caffeine, sleep loss and stress on cognitive performance and mood during U.S. Navy SEAL training. Pyschopharmacology, 164, 250 261.
6. Biggs SN, Smith A, Dorrian J, Reid K, Dawson D, van den Heuvel C, Baulk S (2007) Perception of simulated driving performance after sleep restriction and caffeine. Journal of Psychosomatic Research, 63, 573 577.
7. Parsons WD, Neims AH (1978) Effect of smoking on caffeine clearance. Clinical Pharmacology and Therapeutics, 24, 40 45.
8. Joeres R, Klinker H, Heusler H, Epping J, Zilly W, Richter E (1988) Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. Hepatology, 8, 575 579.
9. Barone JJ, Roberts HR (1996) Caffeine consumption. Food and Chemical Toxicology, 34, 119 129.
10. Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. Journal of Pharmacokinetics and Pharmacodynamics, 28, 481 504.
11. Ette EI, Williams PJ, Lane JR (2004) Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Annals of Pharmacotherapy, 38, 2136 2144.
12. Yu G, Maskray V, Jackson SH, Swift CG, Tiplady B (1991) A comparison of the central nervous system effects of caffeine and theophylline in elderly subjects. British Journal of Clinical Pharmacology, 32, 341 345.
13. Bryant CA, Farmer A, Tiplady B, Keating J, Sherwood R, Swift CG, Jackson SH (1998) Psychomotor performance: investigating the dose-response relationship for caffeine and theophylline in elderly volunteers. European Journal of Clinical Pharmacology, 54, 309 313.
14. Graham TE, Spriet LL (1995) Metabolic, catecholamine, and exercise performance responses to various doses of caffeine. Journal of Applied Physiology, 78, 867 874.
15. Csajka C, Haller CA, Benowitz NL, Verotta D (2005) Mechanistic pharmacokinetic modeling of ephedrine, norephedrine and caffeine in healthy subjects. British Journal of Clinical Pharmacology, 59, 335 345.
16. Parsons WD, Neims AH (1982) Effects of cimetidine on caffeine disposition in smokers and nonsmokers. Clinical Pharmacology and Therapeutics, 31, 656 661.
17. Thomson AH, Kerr S, Wright S (1996) Population pharmacokinetics of caffeine in neonates and young infants. Therapeutic Drug Monitoring, 18, 245 253.
18. Falcão AC, Fernández de Gatta MM, Delgado Iribarnegaray MF, Santos Buelga D, García MJ, Dominguez-Gil A, Lanao JM (1997) Population pharmacokinetics of caffeine in premature neonates. European Journal of Clinical Pharmacology, 52, 211 217.
19. de Leon J, Diaz FJ, Rogers T et al. (2003) A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. Progress in Neuro-psychopharmacology and Biological Psychiatry, 27, 165 171.
20. Rasmussen BB, Brix TH, Kyvik KO, Brosen K (2002) The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics, 12, 473 478.
21. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T (1994) Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiology, Biomarkers & Prevention, 3, 413 421.
22. Yokoi T, Sawada M, Kamataki T (1995) Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. Pharmacogenetics, 5, S65 S69.
23. MacLeod SL, Tang Y-M, Yokoi T, Kamataki T, Doublin S, Lawson B (1998) The role of recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene. Proceedings of American Association of Cancer Research, 39, 396.
24. Hasler JA, Estabrook R, Murray M et al. (1999) Human cytochromes P450. Molecular Aspects of Medicine, 20, 1 137.
25. Bjornsson TD, Wagner JA, Donahue SR et al. (2003) A review and assessment of potential sources of ethnic differences in drug responsiveness. Journal of Clinical Pharmacology, 43, 943 967.
26. Newton R, Broughton LJ, Lind MJ, Morrison PI, Rogers HJ, Bradbrrok ID (1981) Plasma and salivary pharmacokinetics of caffeine in man. European Journal of Clinical Pharmacology, 21, 45 22.
27. Blanchard J, Sawers SJA (1983) The absolute bioavailability of caffeine in man. European Journal of Clinical Pharmacology, 24, 93 98.
28. Lelo A, Birkett DJ, Robson RA, Miners JO (1986) Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. British Journal of Clinical Pharmacology, 22, 177 182.
29. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz S, Shader RI (1997) Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. Journal of Clinical Pharmacology, 37, 693 703.
30. Schiltmeyer B, Klingebiel T, Schwab M et al. (2003) Population pharmacokinetics of oral busulfan in children. Cancer Chemotherapy and Pharmacology, 52, 209 216.